中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
4期
382-385
,共4页
李金%唐其柱%张文斌%向仕钊%胡哲夫
李金%唐其柱%張文斌%嚮仕釗%鬍哲伕
리금%당기주%장문빈%향사쇠%호철부
生脉注射液%扩张型心肌病%Meta分析
生脈註射液%擴張型心肌病%Meta分析
생맥주사액%확장형심기병%Meta분석
Shengmai Injection%Dilated cardiomyopathy%Meta-analysis
目的:评价中药生脉注射液治疗扩张型心肌病的临床疗效。方法计算机检索Cochrane图书馆、PubMed、EMbase、Google学术搜索、中国知网、万方数据库、维普数据库和中国生物医学文献光盘数据库,查找自建库至2013年12月公开发表关于常规基础治疗联用生脉注射液(治疗组)与常规基础治疗(对照组)治疗扩张型心肌病的随机对照试验,同时辅以手检纳入文献的参考文献。按纳入及排除标准进行文献筛选、资料提取和质量评价后,使用RevMan5.2软件进行Meta分析。结果共纳入8项研究,总计481例扩张型心肌病患者。Meta分析结果表明在常规治疗的基础上,联用生脉注射液的治疗组临床疗效优于常规对照组(OR=4.24,95%CI:2.46~7.30,P<0.00001),并可以改善左室射血分数(MD=7.69,95%CI:1.84~13.55,P=0.01)。结论扩张型心肌病患者在常规基础治疗的基础上联用生脉注射液可明显改善患者的临床疗效,但由于纳入研究数目和质量有限,有必要开展更多设计严谨,大样本、多中心的随机对照试验来确证这种趋势。
目的:評價中藥生脈註射液治療擴張型心肌病的臨床療效。方法計算機檢索Cochrane圖書館、PubMed、EMbase、Google學術搜索、中國知網、萬方數據庫、維普數據庫和中國生物醫學文獻光盤數據庫,查找自建庫至2013年12月公開髮錶關于常規基礎治療聯用生脈註射液(治療組)與常規基礎治療(對照組)治療擴張型心肌病的隨機對照試驗,同時輔以手檢納入文獻的參攷文獻。按納入及排除標準進行文獻篩選、資料提取和質量評價後,使用RevMan5.2軟件進行Meta分析。結果共納入8項研究,總計481例擴張型心肌病患者。Meta分析結果錶明在常規治療的基礎上,聯用生脈註射液的治療組臨床療效優于常規對照組(OR=4.24,95%CI:2.46~7.30,P<0.00001),併可以改善左室射血分數(MD=7.69,95%CI:1.84~13.55,P=0.01)。結論擴張型心肌病患者在常規基礎治療的基礎上聯用生脈註射液可明顯改善患者的臨床療效,但由于納入研究數目和質量有限,有必要開展更多設計嚴謹,大樣本、多中心的隨機對照試驗來確證這種趨勢。
목적:평개중약생맥주사액치료확장형심기병적림상료효。방법계산궤검색Cochrane도서관、PubMed、EMbase、Google학술수색、중국지망、만방수거고、유보수거고화중국생물의학문헌광반수거고,사조자건고지2013년12월공개발표관우상규기출치료련용생맥주사액(치료조)여상규기출치료(대조조)치료확장형심기병적수궤대조시험,동시보이수검납입문헌적삼고문헌。안납입급배제표준진행문헌사선、자료제취화질량평개후,사용RevMan5.2연건진행Meta분석。결과공납입8항연구,총계481례확장형심기병환자。Meta분석결과표명재상규치료적기출상,련용생맥주사액적치료조림상료효우우상규대조조(OR=4.24,95%CI:2.46~7.30,P<0.00001),병가이개선좌실사혈분수(MD=7.69,95%CI:1.84~13.55,P=0.01)。결론확장형심기병환자재상규기출치료적기출상련용생맥주사액가명현개선환자적림상료효,단유우납입연구수목화질량유한,유필요개전경다설계엄근,대양본、다중심적수궤대조시험래학증저충추세。
Objective To review the curative effect of Shengmai Injection on dilated cardiomyopathy (DCM). Methods The databases of Cochrane Library, PubMed, EMbase, Goolge Scholar, CNKI, WangFang Database, VIP Database and CBMdisc were retrieved with computer for searching the randomized controlled trials (RCT) about treatment of DCM with routine therapies combining Shengmai Injection (treatment group) and with routine therapies only (control group) published from database establishing time to Dec. 2013 supplemented manually for searching reference. After screening literature, data extracting and quality reviewing according to inclusion and exclusion criteria, the data was given a Meta-analysis by using RevMan5.2 software. Results There were totally 8 RCT included involving 481 patients. The results of Meta-analysis showed that the curative effect was better in treatment group than that in control group (OR=4.24, 95%CI:2.46-7.30, P<0.00001), and LVEF was improved in treatment group (MD=7.69, 95%CI:1.84-13.55, P=0.01). Conclusion The routine therapies combining Shengmai Injection has an improve curative effect on DCM, while more large-sample and multiple-center RCT with rigorous design are required for further identifying this tendency because of limited quantity and quality of this study.